Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
Nanotechnology-based strategies against SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult …
Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course
J Muri, V Cecchinato, A Cavalli, AA Shanbhag… - Nature …, 2023 - nature.com
Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse
symptoms, which can persist for months. While antiviral antibodies are protective, those …
symptoms, which can persist for months. While antiviral antibodies are protective, those …
Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
Immune protection following either vaccination or infection with SARS-CoV-2 is thought to
decrease over time. We designed a retrospective study, conducted at Leumit Health …
decrease over time. We designed a retrospective study, conducted at Leumit Health …
Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is continuously
evolving, and this poses a major threat to antibody therapies and currently authorized …
evolving, and this poses a major threat to antibody therapies and currently authorized …
Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
The humoral arm of innate immunity includes diverse molecules with antibody-like functions,
some of which serve as disease severity biomarkers in coronavirus disease 2019 (COVID …
some of which serve as disease severity biomarkers in coronavirus disease 2019 (COVID …
Current status of therapeutic monoclonal antibodies against SARS-CoV-2
S Kumar, A Chandele, A Sharma - PLoS pathogens, 2021 - journals.plos.org
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has taken a toll on millions
of lives worldwide. Currently, India has the second highest number of active COVID-19 …
of lives worldwide. Currently, India has the second highest number of active COVID-19 …
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued …
diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued …